ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
21 août 2024 14h16 HE
|
ProLynx Inc.
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once monthly. The ProLynx...